About Drugs in Context

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Metrics: SJR/Scimago: Q1 title; H index = 10; SJR = 1.193. Equivalent Impact Factor = 3.07.

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. Other article types are considered.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Submit your article: check the 'AUTHORS' pages for full information.

Latest Article

Brodalumab in psoriasis: evidence to date and clinical potential

Amy C Foulkes BMedSci (Hons), BMBS, MRCP (Derm), PhD, Richard B Warren BSc (Hons), MBChB (Hons), MRCP, PhD

Articles 2019

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?

Francesco Menzella MD, Mirella Biava Msc, Diego Bagnasco MD, PhD, Carla Galeone Msc, Anna Simonazzi MD, Patrizia Ruggiero Msc, Nicola Facciolongo MD

Second-line treatment options in hepatocellular carcinoma

Donatella Marino MD, Clizia Zichi MD, Marco Audisio MD, Elisa Sperti MD, Massimo Di Maio MD

Ketamine as treatment for post-traumatic stress disorder: a review

Felix Liriano, Candace Hatten MD, Thomas L Schwartz MD

Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges

Ahmet Koyuncu MD, Ezgi İnce MD, Erhan Ertekin MD, Raşit Tükel MD

Immunotherapy in non-melanoma skin cancer: updates and new perspectives

Paolo Antonio Ascierto MD, Dirk Schadendorf MD, PhD